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Abstract
Background: Low serum selenium has been associated with lower CD4 counts and greater
mortality among HIV-1-seropositive individuals, but most studies have not controlled for serum
albumin and the presence of an acute phase response.
Methods:  A cross-sectional study was conducted to evaluate relationships between serum
selenium concentrations and CD4 count, plasma viral load, serum albumin, and acute phase
response markers among 400 HIV-1-seropositive women.
Results: In univariate analyses, lower CD4 count, higher plasma viral load, lower albumin, and the
presence of an acute phase response were each significantly associated with lower serum selenium
concentrations. In multivariate analyses including all four of these covariates, only albumin remained
significantly associated with serum selenium. For each 0.1 g/dl increase in serum albumin, serum
selenium increased by 0.8 µg/l (p < 0.001). Women with an acute phase response also had lower
serum selenium (by 5.6 µg/l, p = 0.06).
Conclusion: Serum selenium was independently associated with serum albumin, but not with CD4
count or plasma viral load, in HIV-1-seropositive women. Our findings suggest that associations
between lower serum selenium, lower CD4 count, and higher plasma viral load may be related to
the frequent occurrence of low serum albumin and the acute phase response among individuals
with more advanced HIV-1 infection.
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Background
Nutritional deficiencies have long been recognized as an
important problem among HIV-1-seropositive individu-
als, particularly in resource-limited settings [1]. Micronu-
trient deficiencies have been associated with more rapid
HIV-disease progression and higher HIV-1 related mortal-
ity [2,3]. In some studies, micronutrient supplementation
has delayed time to AIDS and improved survival, suggest-
ing that supplementation could offer a simple and rela-
tively inexpensive strategy to slow HIV-1 progression
[4,5].
Selenium is an antioxidant micronutrient that is an essen-
tial element of selenoproteins, including selenoprotein P
and glutathione peroxidase. Among HIV-1-seropositive
individuals, lower serum selenium concentrations have
been associated with lower CD4 counts, more advanced
HIV-1 disease, and greater HIV-1 related mortality [6-10].
However, most studies have not controlled for low serum
albumin, which binds non-specifically to selenium in
serum, or for the presence of an acute phase response,
which alters hepatic production of albumin and other
serum proteins [11,12]. We sought to determine whether
serum selenium was independently associated with CD4
count or plasma viral load after adjusting for serum albu-
min and the presence of an acute phase response.
Methods
Study design
A cross-sectional study was conducted using baseline data
from 400 HIV-1-seropositive women enrolled in a rand-
omized trial of micronutrient supplementation [13]. Data
were collected between September 1998 and June 2000 at
Coast Provincial General Hospital in Mombasa, Kenya.
Women between 18 and 45 years old were enrolled if they
were not currently or recently (last 3 months) pregnant,
taking vitamin supplements, or using oral contraceptives.
The enrollment criteria were based on the parent trial of
micronutrient supplementation [13]. All participants
were antiretroviral naïve. The protocol was approved by
the institutional review boards of the University of Nai-
robi and the University of Washington, and all women
provided written informed consent.
Detailed procedures and sample collection techniques
have been previously described []. In brief, women were
interviewed regarding demographic, sexual, and medical
characteristics using a standardized questionnaire. A phys-
ical examination was performed. Blood was collected for
lymphocyte subset analysis, quantitation of plasma HIV-
1 RNA, and nutritional assays.
Laboratory methods
Serum samples were protected from light, separated
within 4 hours of collection, and stored at -70°C. Serolog-
ical testing for HIV-1 was performed using an ELISA
(Detect HIV 1/2, BioChem Immunosystems, Montreal,
Canada), and confirmed with a second ELISA (Recom-
bigen, Cambridge Biotech, Worcester, USA). Absolute
CD4 counts were determined using a semiautomated sys-
tem (Zymmune CD4/CD8 Cell Monitoring Kit, Bartels
Inc., Issaquah, USA), which had a lower quantitation
limit of 25 cells/µl. The quantity of HIV-1 RNA in plasma
was determined using the Gen-Probe HIV-1 viral load
assay (Gen-Probe Incorporated, San Diego, USA). The
lower limit of quantification for the assay was 3 copies/
reaction, which was equivalent to 12 copies/ml for the
plasma volumes tested [14]. Serum selenium was quanti-
fied using graphite furnace atomic absorption spectro-
photometry [15]. Serum albumin, C-reactive protein
(CRP), and α1-acid glycoprotein (AGP) were determined
by nephelometry (Dade Behring, Marburg, Germany).
Statistical analysis
Data were analyzed using SPSS 12.0 (SPSS Inc., Chicago,
USA). Low serum selenium was defined as a serum level ≤
85 µg/l [16], a threshold that has been associated with
adverse outcomes in HIV-1 infection [7,8]. An acute phase
response was considered to be present if a participant had
CRP ≥ 1 mg/dl [12] or AGP ≥ 100 mg/dl [17]. Univariate
comparisons were performed using chi-square tests for
dichotomous outcomes and t-tests for continuous out-
comes. Multivariate comparisons were conducted using
logistic and linear regression. Plasma HIV-1 RNA levels
were log10 transformed to approximate a normal distribu-
tion.
Results
Study population
Baseline characteristics of this study population have been
described [13]. In brief, participants had a mean age of 29
years [standard deviation (SD) ± 6] with 7 years (SD ± 4)
of education. Participants were generally of low socioeco-
nomic status, as evidenced by only 35 (9%) having a toilet
in the home. Two hundred twenty (55%) participants
were married. The women had a mean of 3 children (SD
± 2), and 73 (18%) were using injectable progesterone
contraception (depot medroxyprogesterone acetate). The
mean serum selenium concentration was 100 µg/l (SD ±
26).
Comparison of women with low vs. normal serum selenium
Women with low serum selenium had more advanced
immunosuppression, higher plasma viral loads, lower
albumin, more frequent symptoms and signs of HIV-1
infection, and were more likely to have an acute phase
response compared to women with normal serum sele-
nium (Table 1). In a multivariate model including CD4
count, plasma viral load, albumin, and the acute phase
response, only serum albumin concentration and theBMC Infectious Diseases 2006, 6:85 http://www.biomedcentral.com/1471-2334/6/85
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presence of an acute phase response remained signifi-
cantly associated with low serum selenium. When
included in the multivariate model, signs and symptoms
of HIV-1 and body mass index were not independently
associated with serum selenium and their inclusion did
not significantly affect the association between selenium
and albumin or the acute phase response, so these covari-
ates were not included in the final multivariate model.
Correlates of serum selenium
In univariate analyses, higher CD4 count and higher
serum albumin concentrations were associated with
higher serum selenium concentrations, while higher
plasma viral load, the presence of an acute phase
response, and symptoms or signs of HIV-1 disease were
associated with lower selenium concentrations (Table 2).
In a multivariate model including CD4 count, plasma
viral load, albumin, and the acute phase response, only
albumin was significantly associated with serum sele-
nium. Each 0.1 g/dl increase in serum albumin was asso-
ciated with an 0.8 µg/l [95% confidence interval (CI) 0.4–
1.2] increase in serum selenium. Women with an acute
phase response had lower serum selenium concentrations
than women without an acute phase response, although
this association did not reach statistical significance. Signs
or symptoms of HIV-1 and body mass index were not
associated with serum selenium and did not substantially
affect the associations between selenium and albumin or
the acute phase response results, so these variables were
not included in the final multivariate model. In separate
multivariate models evaluating CRP and AGP as continu-
ous covariates, neither of these inflammatory markers was
Table 2: Correlates of Serum Selenium Concentration (µg/l) among 400 HIV-1-Seropositive Women.
Univariate Linear Regression Multivariate Linear Regression
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
CD4 count (per 100 cells/µl increase) 1.8 (0.6, 3.0) 0.004 0.2 (-1.3, 1.7) 0.8
Plasma HIV-1 RNA (per 1 log10 copies/ml increase) -3.5 (-6.1, -0.8) 0.01 0.6 (-2.7, 3.8) 0.7
Serum albumin (per 0.1 g/dl increase) 1.0 (0.7, 1.3) <0.001 0.8 (0.4, 1.2) <0.001
Acute phase response1 -10.8 (-15.8, -6.0) <0.001 -5.4 (-10.9, 0.1) 0.06
HIV-1 symptoms2 -9.5 (-14.9, -4.0) 0.001 - -
HIV-1 signs3 -7.0 (-13.0, -1.1) 0.02 - -
Body mass index (kg/m2) 0.17 (-0.4, 0.7) 0.5 - -
CI – confidence interval
1The presence of C-reactive protein ≥ 1 mg/dl and/or α1-acid glycoprotein ≥ 100 mg/dl.
2 Defined as fever for ≥ 1 month, diarrhea for ≥ 1 month, cough for ≥ 1 month, unintended weight loss of ≥ 5 kg during previous year, or itching 
skin rash during previous year.
3 Defined as the presence of oral thrush, oral hairy leukoplakia, oral ulcer, maculopapular rash, or Kaposi's sarcoma.
Table 1: Comparison of HIV-1-Seropositive Women with Low (≤ 85 µg/l) versus Normal (>85 µg/l) Serum Selenium Concentrations.
Mean (± SD) or Number (%) Multivariate Logistic Regression1
Low serum selenium
(n = 104)
Normal serum selenium
(n = 296)
p-value2 Adjusted Odds Ratio (95% CI) p-value
CD4 count (cells/µl) 216 (± 182) 300 (± 210) <0.001 0.90 (0.77, 1.06)3 0.2
Plasma HIV-1 RNA (log10 of copies/ml) 5.6 (± 0.9) 5.3 (± 1.0) 0.01 0.84 (0.61, 1.17) 0.3
Serum albumin (g/dl) 2.86 (± 0.75) 3.34 (± 0.68) <0.001 0.93 (0.90, 0.97) <0.001
Acute phase response4 73 (70%) 129 (44%) <0.001 1.83 (1.05, 3.18) 0.03
HIV-1 symptoms5 83 (80%) 198 (67%) 0.008 - -
HIV-1 signs6 34 (33%) 57 (19%) 0.01 - -
Body mass index (kg/m2) 21.5 (± 3.5) 22.3 (± 4.7) 0.08 - -
SD – standard deviation; CI – confidence interval
1 CD4 count, plasma HIV-1 RNA, serum albumin were modeled as continuous variables, and the acute phase response was modeled as a 
dichotomous variable.
2 Calculated by using t-tests for continuous variables and χ2 tests for dichotomous variables.
3 Odds ratio is per 100 CD4 cells/µl increase.
4 The presence of C-reactive protein ≥ 1 mg/dl and/or α1-acid glycoprotein ≥ 100 mg/dl.
5 Defined as fever for ≥ 1 month, diarrhea for ≥ 1 month, cough for ≥ 1 month, unintended weight loss of ≥ 5 kg during previous year, or itching 
skin rash during previous year.
6 Defined as the presence of oral thrush, oral hairy leukoplakia, oral ulcer, maculopapular rash, or Kaposi's sarcoma.BMC Infectious Diseases 2006, 6:85 http://www.biomedcentral.com/1471-2334/6/85
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independently associated with serum selenium (data not
shown).
Discussion
In this cross-sectional study of HIV-1-seropositive
women, low serum selenium was independently associ-
ated with serum albumin and with the acute phase
response, but not with CD4 count or plasma viral load.
Further prospective studies may help determine whether
associations between low serum selenium and low CD4
count [6,9] and more advanced HIV-1 disease [10] could
be related to the frequent occurrence of hypoalbumine-
mia and the acute phase response in people with
advanced HIV-1 infection.
Several ingested forms of selenium, including selenome-
thionine, bind non-specifically to albumin for transport
to the liver [11,18-21]. The liver converts these com-
pounds into selenocysteine, which is used to form various
selenoproteins. In total, approximately 55% of selenium
in human serum exists in selenoprotein P, another 17–
32% exists bound to albumin, mostly in the form of
selenomethionine, and only 10% of serum selenium is
not protein bound [11,18,21]. Since low serum albumin
has been independently associated with faster HIV-1 dis-
ease progression and higher mortality, low serum sele-
nium may simply reflect a decline in serum albumin
among people with more active or advanced HIV-1 dis-
ease [6,23].
The presence of an acute phase response is typically asso-
ciated with a decrease of serum albumin and other plasma
proteins [12]. Among HIV-1-seropositive individuals, the
acute phase response has also been associated with low
serum selenium and with HIV-1 disease progression and
mortality [6,24]. One study found that CRP predicts mor-
tality in HIV-1-infected women independent of serum
albumin [25]. Our results suggest that the observed uni-
variate associations between serum selenium and the
acute phase response may have been due, at least in part,
to decreased hepatic production of albumin and other
plasma proteins in HIV-1-seropositive individuals with an
acute phase response [18,22]. There may also be a redistri-
bution of selenium from serum and liver to muscle tissue
during an acute phase response [22].
Our study builds on previous analyses by examining the
relationship between serum selenium concentrations,
CD4 count, and plasma HIV-1 viral load in a large cohort
of untreated HIV-1-seropositive adults. The size of this
study enhanced our ability to conduct detailed multivari-
ate analyses, which demonstrate the lack of a significant
independent association between selenium and CD4 cell
count or plasma viral load.
We have previously published the results of the micronu-
trient supplementation trial in which these women
received six weeks of either a supplement containing B
vitamins, vitamin C, vitamin E, and selenium or an iden-
tical placebo [13]. Following supplementation, women
who received the supplement had slightly higher CD4
counts compared to those who received placebo, an effect
that was also observed in a trial of an otherwise identical
supplement that did not contain selenium [5]. It is not
possible to disentangle the independent effects of sele-
nium from the known effects of those other micronutri-
ents that were provided in the same supplement. Thus, we
were unable to use those longitudinal data to evaluate the
associations between selenium supplementation and
albumin, CD4 count, and plasma viral load.
The findings presented here should be interpreted in the
context of the limitations of this study. Although cross-
sectional studies are useful to define associations, it is not
possible to infer with certainty that low albumin or the
acute phase response were the cause of low measured
serum selenium, although this relationship seems plausi-
ble because a large proportion of serum selenium is pro-
tein bound [18,22]. Regardless of the mechanism, the
confounding bias demonstrated by our analyses was
strong enough to nullify highly significant univariate
associations between serum selenium and CD4 count and
plasma viral load. However, these data cannot rule out the
possibility that low serum selenium or a low antioxidant
status was the cause of low serum albumin. Furthermore,
because hypoalbuminemia may influence the relation-
ship between serum selenium and total body selenium
status, the measured serum selenium may not accurately
reflect total body selenium in advanced HIV-1 infection.
Data on dietary selenium intake were not collected in this
population. Finally, because this study included only
women, these results may not be generalizable to HIV-1-
seropositive men.
The finding that serum selenium is not independently
associated with CD4 count or plasma viral load may help
to explain the results of small randomized and non-rand-
omized trials of selenium supplementation among HIV-1-
seropositive individuals. While one study found an
increase in CD4/CD8 ratio after 12 weeks [26], none have
demonstrated significant effects on the absolute CD4 cell
count or plasma viral load [10,26,27]. However, a benefi-
cial effect of selenium supplementation that is independ-
ent of CD4 count and plasma viral load is possible. In one
randomized trial, selenium supplementation decreased
hospital admissions due to infections among HIV-1
infected adults [28]. The trial did not report changes in
biological markers of HIV-1 disease progression or the
effect on HIV-1-related mortality.BMC Infectious Diseases 2006, 6:85 http://www.biomedcentral.com/1471-2334/6/85
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Conclusion
The results of this investigation demonstrate that serum
selenium was not independently associated with CD4
count or plasma viral load among HIV-1-seropositive
women. These findings indicate that studies assessing the
impact of selenium on HIV-1 surrogate markers, such as
CD4 cell count and plasma viral load, need to control for
serum albumin levels and the presence of an acute phase
response.
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